Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.589
-0.035 (-5.58%)
At close: Apr 28, 2026, 4:00 PM EDT
0.546
-0.043 (-7.32%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Galmed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
3.88M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 5.07M |
| 60 Degrees Pharmaceuticals | 1.41M |
| SciSparc | 1.31M |
| VivoSim Labs | 142.00K |
| AIM ImmunoTech | 88.00K |
| Azitra | 7.50K |
| Pulmatrix | 3.00K |
GLMD News
- 14 days ago - Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - PRNewsWire
- 19 days ago - Galmed Stock Soars On Brain-Penetrating Aramchol Formulation - Benzinga
- 19 days ago - Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - PRNewsWire
- 4 weeks ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - PRNewsWire
- 3 months ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 5 months ago - Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PRNewsWire
- 5 months ago - Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PRNewsWire
- 5 months ago - Galmed Issues CEO Letter to Shareholders - PRNewsWire